Pharming Group (NASDAQ:PHAR) Stock Price Down 2% – Should You Sell?

Pharming Group (NASDAQ:PHAR)’s share price traded down 2% during mid-day trading on Monday . The company traded as low as $8.58 and last traded at $8.75. 5,512 shares traded hands during trading, a decline of 11% from the average session volume of 6,201 shares. The stock had previously closed at $8.93.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Jefferies Financial Group started coverage on shares of Pharming Group in a research report on Monday, December 9th. They set a “buy” rating and a $14.00 price target for the company. Oppenheimer upped their target price on shares of Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a research report on Friday, March 14th. Finally, HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research report on Thursday, March 20th.

Pharming Group Stock Down 1.3 %

The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The firm has a market cap of $592.89 million, a P/E ratio of -33.52 and a beta of -0.10. The firm’s 50 day moving average is $8.86 and its two-hundred day moving average is $8.65.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings data on Thursday, March 13th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). The firm had revenue of $92.70 million during the quarter, compared to the consensus estimate of $76.67 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. As a group, research analysts anticipate that Pharming Group will post -0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.